The story of copyright's flagship drug presents a complex case for stakeholders in the drug sector. While initially a tremendous success, generating huge profits, the exclusivity end and the subsequent entry of cheaper competitors have significantly affected earnings. This raises questions about the long-term viability of related drug innovations a